vs
Side-by-side financial comparison of MGIC INVESTMENT CORP (MTG) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
MGIC INVESTMENT CORP is the larger business by last-quarter revenue ($297.1M vs $177.4M, roughly 1.7× Pacira BioSciences, Inc.). MGIC INVESTMENT CORP runs the higher net margin — 55.6% vs 1.6%, a 54.0% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -3.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -1.4%).
MGIC Investment Corporation NYSE: MTG ("MGIC") is a provider of private mortgage insurance in the United States. The company is headquartered in Milwaukee, Wisconsin.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
MTG vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $297.1M | $177.4M |
| Net Profit | $165.3M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 55.6% | 1.6% |
| Revenue YoY | -3.0% | 5.0% |
| Net Profit YoY | -10.9% | — |
| EPS (diluted) | $0.76 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $297.1M | $177.4M | ||
| Q4 25 | $298.7M | $196.9M | ||
| Q3 25 | $304.5M | $179.5M | ||
| Q2 25 | $304.2M | $181.1M | ||
| Q1 25 | $306.2M | $168.9M | ||
| Q4 24 | $301.4M | $187.3M | ||
| Q3 24 | $306.6M | $168.6M | ||
| Q2 24 | $305.3M | $178.0M |
| Q1 26 | $165.3M | $2.9M | ||
| Q4 25 | $169.3M | — | ||
| Q3 25 | $191.1M | $5.4M | ||
| Q2 25 | $192.5M | $-4.8M | ||
| Q1 25 | $185.5M | $4.8M | ||
| Q4 24 | $184.7M | — | ||
| Q3 24 | $200.0M | $-143.5M | ||
| Q2 24 | $204.2M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 71.2% | 1.2% | ||
| Q3 25 | 77.2% | 3.5% | ||
| Q2 25 | 80.9% | 4.7% | ||
| Q1 25 | 76.6% | 1.2% | ||
| Q4 24 | 77.9% | 13.2% | ||
| Q3 24 | 82.9% | -82.8% | ||
| Q2 24 | 85.1% | 15.9% |
| Q1 26 | 55.6% | 1.6% | ||
| Q4 25 | 56.7% | — | ||
| Q3 25 | 62.8% | 3.0% | ||
| Q2 25 | 63.3% | -2.7% | ||
| Q1 25 | 60.6% | 2.8% | ||
| Q4 24 | 61.3% | — | ||
| Q3 24 | 65.2% | -85.1% | ||
| Q2 24 | 66.9% | 10.6% |
| Q1 26 | $0.76 | $0.07 | ||
| Q4 25 | $0.75 | $0.05 | ||
| Q3 25 | $0.83 | $0.12 | ||
| Q2 25 | $0.81 | $-0.11 | ||
| Q1 25 | $0.75 | $0.10 | ||
| Q4 24 | $0.71 | $0.38 | ||
| Q3 24 | $0.77 | $-3.11 | ||
| Q2 24 | $0.77 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $235.1M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.0B | $653.9M |
| Total Assets | $6.4B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $235.1M | $144.3M | ||
| Q4 25 | $369.0M | $238.4M | ||
| Q3 25 | $266.9M | $246.3M | ||
| Q2 25 | $294.9M | $445.9M | ||
| Q1 25 | $207.0M | $493.6M | ||
| Q4 24 | $229.5M | $484.6M | ||
| Q3 24 | $288.6M | $453.8M | ||
| Q2 24 | $281.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $5.0B | $653.9M | ||
| Q4 25 | $5.1B | $693.1M | ||
| Q3 25 | $5.2B | $727.2M | ||
| Q2 25 | $5.2B | $757.8M | ||
| Q1 25 | $5.1B | $798.5M | ||
| Q4 24 | $5.2B | $778.3M | ||
| Q3 24 | $5.3B | $749.6M | ||
| Q2 24 | $5.1B | $879.3M |
| Q1 26 | $6.4B | $1.2B | ||
| Q4 25 | $6.6B | $1.3B | ||
| Q3 25 | $6.6B | $1.3B | ||
| Q2 25 | $6.5B | $1.5B | ||
| Q1 25 | $6.5B | $1.6B | ||
| Q4 24 | $6.5B | $1.6B | ||
| Q3 24 | $6.7B | $1.5B | ||
| Q2 24 | $6.5B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MTG
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
